CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 173 filers reported holding CLOVIS ONCOLOGY INC in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
Q2 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
Q1 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
Q4 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
Q3 2021 | $0 | -100.0% | 100 | 0.0% | 0.00% | – |
Q2 2021 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q1 2021 | $1,000 | – | 100 | 0.0% | 0.00% | – |
Q4 2020 | $0 | -100.0% | 100 | 0.0% | 0.00% | – |
Q3 2020 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q2 2020 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q1 2020 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q4 2019 | $1,000 | – | 100 | 0.0% | 0.00% | – |
Q3 2019 | $0 | -100.0% | 100 | 0.0% | 0.00% | – |
Q1 2019 | $2,000 | -97.8% | 100 | -90.0% | 0.00% | -100.0% |
Q3 2015 | $92,000 | +4.5% | 1,000 | 0.0% | 0.02% | +18.8% |
Q2 2015 | $88,000 | +18.9% | 1,000 | 0.0% | 0.02% | +14.3% |
Q1 2015 | $74,000 | +32.1% | 1,000 | 0.0% | 0.01% | +27.3% |
Q4 2014 | $56,000 | +24.4% | 1,000 | 0.0% | 0.01% | +22.2% |
Q3 2014 | $45,000 | +9.8% | 1,000 | 0.0% | 0.01% | +12.5% |
Q2 2014 | $41,000 | -40.6% | 1,000 | 0.0% | 0.01% | -42.9% |
Q1 2014 | $69,000 | – | 1,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |